Adverse Outcome Pathways: An update on progress and some near-term applications
This record is part of
a dataset collected by the EU Commission in June-September 2018
. Some of these links will therefore die out with time.
Please see the
overview of courses maintained by ETPLAS
or contact Norecopa for more information.
Owner/Developer: The European Society of Toxicology In Vitro and The American Society for Cellular and Computational Toxicology (ESTIV, ASCCT)
| Country: |
Belgium |
|---|---|
| Languages: |
English |
| Url: |
https://www.ascctox.org/upcoming-webinar/40 |
| Created: |
20 September 2018 |
| Description: | Adverse outcome pathways are currently gaining momentum, especially in view of their many potential applications as pragmatic tools in the fields of human toxicology, ecotoxicology and risk assessment. Among the many applications of adverse outcome pathways are the establishment of (quantitative) structure-activity relationships, the development of novel in vitro toxicity screening tests, and the elaboration of integrated approaches to testing and assessment. The specific application of an adverse outcome pathway is dictated by its degree of maturity. In this respect, the vast majority of currently available adverse outcome pathways are qualitative in nature and/or focus on only one molecular initiating event and a linear series of adverse key events. This may be sufficient for some purposes, yet most applications in toxicology and risk assessment require a more advanced level of adverse outcome pathway development. In this webinar, the cases of skin and respiratory sensitization will be discussed to demonstrate how an AOP can lead to the regulatory applicability of integrated approaches to testing and assessment (IATA). Discussion of the evolution of the OECD AOP and Test Guidelines Programmes in this context will be provided. Furthermore, focus will be put on cholestatic liver toxicity, for which an adverse outcome pathway network is currently being developed that may serve as the basis of an innovative in vitro testing platform |
| References: | https://register.gotowebinar.com/register/3496904766293515011 |
| Format: |
Webinars |
| Presence: |
Optional / Voluntary |
| Access: |
Free |
| Content type: |
Theoretical |
| Duration: |
1 h |
| Target audience: |
Students, Researchers, Regulators and policy-makers, Teachers and educators, Technicians, Managers, Scientific officers / Project managers, Professionals (e.g. veterinarians), General public |
| Target sectors: |
Academia, Industry, Governmental bodies, Contract Research Organizations (CROs), Consulting, SMEs |
| Educational level: |
University (Bachelor), University (Master), University (Doctoral education), Postdoctoral (teaching and research), Continuing Professional Development |
| 3rs relevance: |
Replacement |
| Topics covered: |
Computational methods |
| 3rs coverage: |
Full coverage (a dedicated course) |
| Details on the topic or technology covered: |
Adverse outcome pathways are currently gaining momentum, especially in view of their many potential applications as pragmatic tools in the fields of human toxicology, ecotoxicology and risk assessment. Among the many applications of adverse outcome pathways are the establishment of (quantitative) structure-activity relationships, the development of novel in vitro toxicity screening tests, and the elaboration of integrated approaches to testing and assessment. The specific application of an adverse outcome pathway is dictated by its degree of maturity. In this respect, the vast majority of currently available adverse outcome pathways are qualitative in nature and/or focus on only one molecular initiating event and a linear series of adverse key events. This may be sufficient for some purposes, yet most applications in toxicology and risk assessment require a more advanced level of adverse outcome pathway development. In this webinar, the cases of skin and respiratory sensitization will be discussed to demonstrate how an AOP can lead to the regulatory applicability of integrated approaches to testing and assessment (IATA). Discussion of the evolution of the OECD AOP and Test Guidelines Programmes in this context will be provided. Furthermore, focus will be put on cholestatic liver toxicity, for which an adverse outcome pathway network is currently being developed that may serve as the basis of an innovative in vitro testing platform. |
| Legislative framework: |
Test guidelines (OECD, ISO, etc.) |
Did you find what you were looking for?
Yes, I found it! No, I did not!Thanks for your feedback! Please note that we cannot reply to you unless you send us an email.
What are you looking for?
We value your feedback so we can improve the information on the page. Please add your email address if you would like a reply. Thank you in advance for your help.!
Please contact us by email if you have any questions.